公开(公告)号：US20240200146A1

公开(公告)日：2024-06-20

申请号：US18516552

申请日：2023-11-21

Applicant: Genentech, Inc.

Inventor： Christiaan Nicolaas Klijn ,  Shiva Malek ,  Ivana Yen

IPC: C12Q1/6886 ,  A61K31/519 ,  A61K31/553 ,  A61K45/06 ,  A61P35/00

CPC classification number: C12Q1/6886 ,  A61K31/519 ,  A61K31/553 ,  A61K45/06 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).

公开(公告)号：US20240239895A1

公开(公告)日：2024-07-18

申请号：US18554236

申请日：2022-04-07

Applicant: Genentech, Inc. ,  Hanmi Pharm. Co., Ltd.

Inventor： Darlene Dela Cruz ,  Shiva Malek ,  Ehud Segal ,  Ivana Yen Yen YEN ,  In Hwan BAE ,  Kwee Hyun SUH

IPC: C07K16/28 ,  A61K31/519 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2827 ,  A61K31/519 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/545

Abstract: A combination therapy comprising a RAF inhibitor and a PD-1 axis inhibitor is provided for the treatment of cancer characterized by a mutated MAPK signaling pathway.

公开(公告)号：US20240173329A1

公开(公告)日：2024-05-30

申请号：US18549622

申请日：2022-03-08

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc. ,  Hanmi Pharm. Co., Ltd.

Inventor： Joanne Adamkewicz ,  Michael John Dolton ,  Shiva Malek ,  Piia Thomas ,  Jennifer Eng-Wong ,  Yibing Yan ,  Young Hoon KIM ,  Young Gil AHN ,  Yu Yon KIM

IPC: A61K31/519 ,  A61K31/4523 ,  A61P35/04

CPC classification number: A61K31/519 ,  A61K31/4523 ,  A61P35/04

Abstract: Provided are methods for the use of belvarafenib to treat brain cancer including metastatic brain cancer carrying a BRAF mutation, a NRAS mutation, a KRAS mutation, or a combination thereof.

公开(公告)号：US11859252B2

公开(公告)日：2024-01-02

申请号：US16644902

申请日：2018-09-07

Applicant: Genentech, Inc.

Inventor： Christiaan Nicolaas Klijn ,  Shiva Malek ,  Ivana Yen

IPC: C12Q1/6886 ,  A61P35/00 ,  A61K31/519 ,  A61K31/553 ,  A61K45/06

CPC classification number: C12Q1/6886 ,  A61K31/519 ,  A61K31/553 ,  A61K45/06 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).

公开(公告)号：US20150164895A1

公开(公告)日：2015-06-18

申请号：US14284027

申请日：2014-05-21

Applicant: GENENTECH, INC.

Inventor： Georgia Hatzivassiliou ,  Shiva Malek

IPC: A61K31/517 ,  G01N33/574

CPC classification number: A61K31/517 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/5743 ,  G01N33/57438 ,  G01N33/57449 ,  G01N33/57492 ,  G01N33/57496 ,  G01N2333/91205 ,  G01N2333/914 ,  G01N2800/52

Abstract: The present invention relates to prognostic methods for identifying tumors that are not susceptible to B-Raf inhibitor treatment by detecting mutations in a K-ras gene or protein or by detecting overexpression of RTKs and/or their ligands. Kits are also disclosed for carrying out the methods.

Abstract translation: 本发明涉及通过检测K-ras基因或蛋白质中的突变或通过检测RTK和/或其配体的过表达鉴定对B-Raf抑制剂治疗不敏感的肿瘤的预后方法。 还披露了用于实施这些方法的试剂盒。